James Fordyce
Fondateur chez Critical Biologics Corp.
Profil
James W.
Fordyce is the founder of Critical Biologics Corp.
(founded in 2006) and Lotus Tissue Repair, Inc. (founded in 2011).
He holds the title of Director at Critical Biologics Corp.
and is the Chief Financial Officer & Director at Lotus Tissue Repair, Inc. in 2011.
Mr. Fordyce is also the founder of Chromaderm, Inc., FIBRX Derm, Inc...
Mr. Fordyce's current job(s) include being the Chairman at Albert & Mary Lasker Foundation, Director at VelQuest Corp.
since 2000, and Managing Partner at MEDNA Partners LLC since 2001.
Mr. Fordyce's former job(s) include being an Independent Director at Dyax Corp.
from 2011 to 2016, Director at Ore Pharmaceuticals, Inc., Director at Ore Holdings, Inc. from 2009 to 2010, and an Advisor at Darwin Ventures LLC.
Mr. Fordyce's education history includes an MBA from Harvard University in 1970, an undergraduate degree from the University of Pennsylvania in 1964, and an undergraduate degree from Magdalen College School Oxford Ltd in 1967.
Postes actifs de James Fordyce
| Sociétés | Poste | Début |
|---|---|---|
VelQuest Corp.
 VelQuest Corp. Packaged SoftwareTechnology Services VelQuest Corp. provides integrated compliance management solutions. The company's software is used by pharmaceutical companies to reduce compliance risk, liberate valuable resources and add value to existing document management and IT resources. Its SmartLab GMP Electronic Notebook System is built on electronic process management and compliance core operating system to provide the foundation for compliance based activities in the life science markets. The firm's services include planning and consulting, implementation, validation, customer education, field Service and customer support. VelQuest was founded in January, 1999 and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | 01/01/2000 |
| Albert & Mary Lasker Foundation | Directeur/Membre du Conseil | 29/01/2010 |
MEDNA Partners LLC
 MEDNA Partners LLC Investment ManagersFinance MEDNA Partners LLC private advisory firm. The company is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/01/2001 |
Critical Biologics Corp.
 Critical Biologics Corp. Medical SpecialtiesHealth Technology Critical Biologics Corp. develops and commercializes diagnostics and therapeutics drugs. The firm focuses in the development of a theranostic platform to screen and treat both acute and chronic patients with low plasma gelsolin levels (hypogelsolinemia) at high risk of life-threatening complications. The company was founded by James W. Fordyce, Terence S. Russell, Shun Lee Po, and Thomas P. Stossel in 2006 and is headquartered in Cambridge, MA. | Fondateur | 01/01/2006 |
FIBRX Derm, Inc.
 FIBRX Derm, Inc. Pharmaceuticals: MajorHealth Technology FIBRX Derm, Inc. develops anti-scarring therapeutic for patients with Dystrophic Epidermolysis Bullosa. The company was founded by Mark de Souza, James W. Fordyce and Erkki Ruoslahti and is headquartered in Berkeley, CA. | Fondateur | - |
Chromaderm, Inc.
 Chromaderm, Inc. BiotechnologyHealth Technology Chromaderm, Inc. operates as a clinical stage biotech company. It develops topical PKC-beta inhibitor. The company was founded by Barbara A. Gilchrest, Mark de Souza and James W. Fordyce and is headquartered in Cambridge, MA. | Fondateur | - |
Anciens postes connus de James Fordyce
| Sociétés | Poste | Fin |
|---|---|---|
| DYAX CORP. | Directeur/Membre du Conseil | 22/01/2016 |
| ORE HOLDINGS INC | Directeur/Membre du Conseil | 12/02/2010 |
Lotus Tissue Repair, Inc.
 Lotus Tissue Repair, Inc. Pharmaceuticals: MajorHealth Technology Lotus Tissue Repair, Inc. develops dermatologic treatment technologies. Its solutions include a protein replacement therapy for the treatment of dystrophic epidermolysis bullosa, a group of genetic skin disease. The company was founded by Mei Chen, Mark P. de Souza, Philip R. Reilly, David Woodley and James W. Fordyce in 2011 and is headquartered in Lexington, MA. | Fondateur | - |
| ░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
| ░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de James Fordyce
| Harvard University | Masters Business Admin |
| University of Pennsylvania | Undergraduate Degree |
| Magdalen College School Oxford Ltd | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
Dyax Corp.
 Dyax Corp. Pharmaceuticals: MajorHealth Technology Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA. | Health Technology |
VelQuest Corp.
VelQuest Corp. Packaged SoftwareTechnology Services VelQuest Corp. provides integrated compliance management solutions. The company's software is used by pharmaceutical companies to reduce compliance risk, liberate valuable resources and add value to existing document management and IT resources. Its SmartLab GMP Electronic Notebook System is built on electronic process management and compliance core operating system to provide the foundation for compliance based activities in the life science markets. The firm's services include planning and consulting, implementation, validation, customer education, field Service and customer support. VelQuest was founded in January, 1999 and is headquartered in San Diego, CA. | Technology Services |
Critical Biologics Corp.
Critical Biologics Corp. Medical SpecialtiesHealth Technology Critical Biologics Corp. develops and commercializes diagnostics and therapeutics drugs. The firm focuses in the development of a theranostic platform to screen and treat both acute and chronic patients with low plasma gelsolin levels (hypogelsolinemia) at high risk of life-threatening complications. The company was founded by James W. Fordyce, Terence S. Russell, Shun Lee Po, and Thomas P. Stossel in 2006 and is headquartered in Cambridge, MA. | Health Technology |
| Albert & Mary Lasker Foundation | |
MEDNA Partners LLC
MEDNA Partners LLC Investment ManagersFinance MEDNA Partners LLC private advisory firm. The company is headquartered in Cambridge, MA. | Finance |
Darwin Ventures LLC
 Darwin Ventures LLC Investment ManagersFinance Darwin Ventures LLC (Darwin Ventures) is a venture capital founded in 2002 by Peter Freudenthal and Frank R. Caufield. The firm is headquartered in Burlingame, California. | Finance |
Ore Pharmaceuticals, Inc.
 Ore Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ore Pharmaceuticals, Inc. operates as a drug development company, which developed drug candidates for therapeutic uses. The firm marketed its drug repositioning capabilities to pharmaceutical companies based in North America, Japan and Europe. The company was founded in September 1994 and was headquartered in Wellesley, MA. | Health Technology |
Ore Holdings, Inc.
 Ore Holdings, Inc. Financial ConglomeratesFinance Ore Holdings, Inc. is engaged in the provision of investment management services. It focuses on strategic investments aimed at enhancing the value of the entities within its portfolio. The company was founded in September 1994 and is headquartered in New York, NY. | Finance |
Lotus Tissue Repair, Inc.
Lotus Tissue Repair, Inc. Pharmaceuticals: MajorHealth Technology Lotus Tissue Repair, Inc. develops dermatologic treatment technologies. Its solutions include a protein replacement therapy for the treatment of dystrophic epidermolysis bullosa, a group of genetic skin disease. The company was founded by Mei Chen, Mark P. de Souza, Philip R. Reilly, David Woodley and James W. Fordyce in 2011 and is headquartered in Lexington, MA. | Health Technology |
Chromaderm, Inc.
Chromaderm, Inc. BiotechnologyHealth Technology Chromaderm, Inc. operates as a clinical stage biotech company. It develops topical PKC-beta inhibitor. The company was founded by Barbara A. Gilchrest, Mark de Souza and James W. Fordyce and is headquartered in Cambridge, MA. | Health Technology |
FIBRX Derm, Inc.
FIBRX Derm, Inc. Pharmaceuticals: MajorHealth Technology FIBRX Derm, Inc. develops anti-scarring therapeutic for patients with Dystrophic Epidermolysis Bullosa. The company was founded by Mark de Souza, James W. Fordyce and Erkki Ruoslahti and is headquartered in Berkeley, CA. | Health Technology |